Fluoro Pharma

Shaping the Future of Molecular PET Imaging

FluoroPharma is developing breakthrough molecular imaging agents for positron emission tomography (PET) and fluorescence imaging that will fulfill critical unmet medical needs. The company’s agents will give clinicians important tools for the detection and assessment of pathology before clinical manifestations of disease.

Technology Overview:
Learn about our technology platform & molecular imaging agents.

Products:
Learn about our cardiovascular diagnostic products: CardioPET, BFPET & VasoPET.

Market Overview:
Understand the market potential for our products.

Clinical Trials:
Learn about our current clinical trials and IND filing.